537 related articles for article (PubMed ID: 34747718)
41. DNA damage response alterations in clear cell renal cell carcinoma: clinical, molecular, and prognostic implications.
Jing X; Qin X; Liu H; Liu H; Wang H; Qin J; Zhang Y; Cao S; Fan X
Eur J Med Res; 2024 Feb; 29(1):107. PubMed ID: 38326910
[TBL] [Abstract][Full Text] [Related]
42. Homologous recombination repair gene mutations in colorectal cancer favors treatment of immune checkpoint inhibitors.
Lin Y; Luo S; Luo M; Lu X; Li Q; Xie M; Huang Y; Liao X; Zhang Y; Li Y; Liang R
Mol Carcinog; 2023 Sep; 62(9):1271-1283. PubMed ID: 37232365
[TBL] [Abstract][Full Text] [Related]
43. Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers.
Ying J; Yang L; Yin JC; Xia G; Xing M; Chen X; Pang J; Wu Y; Bao H; Wu X; Shao Y; Zhu L; Cheng X
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34479923
[TBL] [Abstract][Full Text] [Related]
44. Single-cell dissection reveals the role of DNA damage response patterns in tumor microenvironment components contributing to colorectal cancer progression and immunotherapy.
Shen X; Mo S; Wang Y; Lin L; Liu Y; Weng M; Gu W; Nakajima T
Genes Cells; 2023 May; 28(5):348-363. PubMed ID: 36811212
[TBL] [Abstract][Full Text] [Related]
45. Somatic mutations in DCC are associated with genomic instability and favourable outcomes in melanoma patients treated with immune checkpoint inhibitors.
Li Y; Wang Q; Chen Y; Zhao L
Br J Cancer; 2022 Nov; 127(8):1411-1423. PubMed ID: 35871235
[TBL] [Abstract][Full Text] [Related]
46. Tumor immune profiles noninvasively estimated by FDG PET with deep learning correlate with immunotherapy response in lung adenocarcinoma.
Park C; Na KJ; Choi H; Ock CY; Ha S; Kim M; Park S; Keam B; Kim TM; Paeng JC; Park IK; Kang CH; Kim DW; Cheon GJ; Kang KW; Kim YT; Heo DS
Theranostics; 2020; 10(23):10838-10848. PubMed ID: 32929383
[No Abstract] [Full Text] [Related]
47. A score of DNA damage repair pathway with the predictive ability for chemotherapy and immunotherapy is strongly associated with immune signaling pathway in pan-cancer.
Ding K; He Y; Wei J; Fu S; Wang J; Chen Z; Zhang H; Qu Y; Liang K; Gong X; Qiu L; Chen D; Xiao B; Du H
Front Immunol; 2022; 13():943090. PubMed ID: 36081518
[TBL] [Abstract][Full Text] [Related]
48. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
49. DNA repair and immune checkpoint blockade response.
Guo JA; Alshalalfa M; Kim DY; Hoffman HI; Shiau C; Su J; Hwang WL; Mahal BA
Cancer Genet; 2022 Jun; 264-265():1-4. PubMed ID: 35245846
[TBL] [Abstract][Full Text] [Related]
50. DNA Damage Response Evaluation Provides Novel Insights for Personalized Immunotherapy in Glioma.
Chen M; Huang B; Zhu L; Wang Q; Pang Y; Cheng M; Lian H; Liu M; Zhao K; Xu S; Zhang J; Zhong C
Front Immunol; 2022; 13():875648. PubMed ID: 35720326
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
Yin M; Grivas P; Wang QE; Mortazavi A; Emamekhoo H; Holder SL; Drabick JJ; Woo MS; Pal S; Vasekar M; Folefac E; Clinton SK; Monk P; Joshi M
Oncologist; 2020 Aug; 25(8):680-688. PubMed ID: 32275806
[TBL] [Abstract][Full Text] [Related]
52. Association between DNA damage repair gene somatic mutations and immune-related gene expression in ovarian cancer.
Tian W; Shan B; Zhang Y; Ren Y; Liang S; Zhao J; Zhao Z; Wang G; Zhao X; Peng D; Bi R; Cai S; Bai Y; Wang H
Cancer Med; 2020 Mar; 9(6):2190-2200. PubMed ID: 31991061
[TBL] [Abstract][Full Text] [Related]
53. Prevalence of Homologous Recombination Pathway Gene Mutations in Melanoma: Rationale for a New Targeted Therapeutic Approach.
Kim KB; Soroceanu L; de Semir D; Millis SZ; Ross J; Vosoughi E; Dar AA; Nosrati M; Desprez PY; Ice R; Chen M; Chetal K; Bhattacharjee A; Moretto J; Leong SP; Singer MI; Parrett BM; Minor DR; McAllister S; Miller JR; Salomonis N; Kashani-Sabet M
J Invest Dermatol; 2021 Aug; 141(8):2028-2036.e2. PubMed ID: 33610559
[TBL] [Abstract][Full Text] [Related]
54. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
55. The association of sex-biased ATRX mutation in female gastric cancer patients with enhanced immunotherapy-related anticancer immunity.
Ge Y; Wei F; Du G; Fei G; Li W; Li X; Chu J; Wei P
BMC Cancer; 2021 Mar; 21(1):240. PubMed ID: 33678158
[TBL] [Abstract][Full Text] [Related]
56. Matter of TIME: the tumor-immune microenvironment of mesothelioma and implications for checkpoint blockade efficacy.
Harber J; Kamata T; Pritchard C; Fennell D
J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518291
[TBL] [Abstract][Full Text] [Related]
57. Systemic inflammation shapes clinical outcomes in response to immune checkpoint blockade treatment: moving toward optimizing antitumor immunity.
Zheng M
J Immunother Cancer; 2023 Mar; 11(3):. PubMed ID: 36889809
[TBL] [Abstract][Full Text] [Related]
58. Co-Occurring Alteration of NOTCH and DDR Pathways Serves as Novel Predictor to Efficacious Immunotherapy in NSCLC.
Zhang Z; Gu Y; Su X; Bai J; Guan W; Ma J; Luo J; He J; Zhang B; Geng M; Xia X; Guan Y; Shen C; Chen C
Front Oncol; 2021; 11():659321. PubMed ID: 33968765
[TBL] [Abstract][Full Text] [Related]
59. Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
Jin J; Cao J; Li B; Li T; Zhang J; Cao J; Zhao M; Wang L; Wang B; Tao Z; Hu X
Cancer; 2023 Mar; 129(6):845-859. PubMed ID: 36655350
[TBL] [Abstract][Full Text] [Related]
60. ATM Mutations Benefit Bladder Cancer Patients Treated With Immune Checkpoint Inhibitors by Acting on the Tumor Immune Microenvironment.
Yi R; Lin A; Cao M; Xu A; Luo P; Zhang J
Front Genet; 2020; 11():933. PubMed ID: 32922441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]